Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.

Strader CR, Pearce CJ, Oberlies NH.

J Nat Prod. 2011 Apr 25;74(4):900-7. doi: 10.1021/np2000528. Review.

PMID:
21456524
2.

Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.

Chiba K, Adachi K.

Future Med Chem. 2012 Apr;4(6):771-81. doi: 10.4155/fmc.12.25. Review.

PMID:
22530640
3.

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P.

Nat Rev Drug Discov. 2010 Nov;9(11):883-97. doi: 10.1038/nrd3248. Review.

PMID:
21031003
4.

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.

Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A.

Neurology. 2011 Feb 22;76(8 Suppl 3):S20-7. doi: 10.1212/WNL.0b013e31820db341. Review.

PMID:
21339487
5.
6.

Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.

Hiestand PC, Rausch M, Meier DP, Foster CA.

Prog Drug Res. 2008;66:361, 363-81. Review.

PMID:
18416311
8.

FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.

Baumruker T, Billich A, Brinkmann V.

Expert Opin Investig Drugs. 2007 Mar;16(3):283-9. Review.

PMID:
17302523
9.

Synthetic sphingosine 1-phosphate receptor modulators--opportunities and potential pitfalls.

Bolli MH, Lescop C, Nayler O.

Curr Top Med Chem. 2011;11(6):726-57. Review.

PMID:
21261590
10.

Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.

Ingwersen J, Aktas O, Kuery P, Kieseier B, Boyko A, Hartung HP.

Clin Immunol. 2012 Jan;142(1):15-24. doi: 10.1016/j.clim.2011.10.008. Review.

PMID:
21669553
11.

Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.

Lee CW, Choi JW, Chun J.

Arch Pharm Res. 2010 Oct;33(10):1567-74. doi: 10.1007/s12272-010-1008-5. Review.

PMID:
21052934
12.

Fingolimod is a potential novel therapy for multiple sclerosis.

Aktas O, Küry P, Kieseier B, Hartung HP.

Nat Rev Neurol. 2010 Jul;6(7):373-82. doi: 10.1038/nrneurol.2010.76. Review.

PMID:
20551946
13.

Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.

Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, Mir A.

Pharmacol Ther. 2008 Jan;117(1):77-93. Review.

PMID:
17961662
14.

Molecular targets of FTY720 (fingolimod).

Pitman MR, Woodcock JM, Lopez AF, Pitson SM.

Curr Mol Med. 2012 Dec;12(10):1207-19. Review.

PMID:
22834825
15.
16.

Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.

Chiba K, Matsuyuki H, Maeda Y, Sugahara K.

Cell Mol Immunol. 2006 Feb;3(1):11-9. Review.

17.
18.

[Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].

Tar L, Vécsei L.

Ideggyogy Sz. 2012 Mar 30;65(3-4):83-100. Review. Hungarian.

PMID:
23136726
19.

Fingolimod: a novel immunosuppressant for multiple sclerosis.

Brown BA, Kantesaria PP, McDevitt LM.

Ann Pharmacother. 2007 Oct;41(10):1660-8. Review.

PMID:
17785617
20.

[Fingolimod - a new immunomodulator].

Friedrich FW, Eschenhagen T.

Dtsch Med Wochenschr. 2009 Oct;134(42):2127-31. doi: 10.1055/s-0029-1241903. Review. German.

PMID:
19809964
Items per page

Supplemental Content

Support Center